Fig. 3From: Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysisTornado diagram of one-way sensitive analysis. (Note: SG, Sacituzumab govitecan; TPC, single-agent chemotherapy of physician’s choice; ICER, incremental cost-effectiveness ratio)Back to article page